Immunosuppression and Long-Term Survival after Heart Transplantation

References

• 1 Taylor D O, Edwards L B, Boucek M M. et al . International Society for Heart and Lung Transplantation: 24th official adult heart transplant report: 2007.  J Heart Lung Transplant. 2007;  8 769-781
• 2 Norman D. Action, efficacy and toxicities: anti-CD25 monoclonal antibodies. Norman DJ, Turka LA Primer on transplantation. New York; American Society of Transplantation 2001: 87-98
• 3 Hersberger R E, Starling R C, Eisen H J. et al . Daclizumab to prevent rejection after heart transplantation.  N Engl J Med. 2005;  352 2705-2713
• 4 Zhang R, Haverich A, Strüber M. et al . Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin.  J Heart Lung Transplant. 2008;  27 603-609
• 5 Eisen H J, Kobashigawa J, Keogh A. et al . Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.  J Heart Lung Transplant. 2005;  24 517-525
• 6 O'Neill J O, Edwards L B, Taylor D O. Myocophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the Transplant Registry of the ISHLT.  J Heart Lung Transplant. 2006;  25 1186-1191
• 7 Kobashigawa J, Tobis J M, Mentzer R M. et al . Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial.  Am J Transplant. 2006;  6 993-997
• 8 Kobashigawa J, Miller L, Renlund D. et al . A randomized active-controlled trial of myocophenolate mofetil in heart transplant recipients.  Transplantation. 1998;  66 507-515
• 9 Hamour I M, Lyster H S, Burke M M. et al . Myocophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplanted patients.  Transplantation. 2007;  83 570-576
• 10 Kaczmarek I, Ertl B, Schmauss D. et al . Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.  J Heart Lung Transplant. 2006;  25 550-556
• 11 Hosenpud J D, Bennet L E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the joint UNOS/ISHLT Thoracic Registry.  Transplantation. 2001;  72 1662-1665
• 12 Angermann C E, Störk S, Costard-Jäckle A. et al . Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients. The IMPROVED multi-center study.  European Heart J. 2004;  25 1626-1634
• 13 Vigano M, Tuzcu M, Benza R. et al . Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: a 24 month analysis.  J Heart Lung Transplant. 2007;  26 584-592
• 14 Lehmkuhl H B, Mai D, Dandel M. et al . Observational study with Everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.  J Heart Lung Transplant. 2007;  26 700-704
• 15 Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.  J Heart Lung Transplant. 2007;  26 557-564
• 16 Morrisett J D, Abdel-Fattah G, Kahan B D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.  Transplant Proc. 2003;  35 (Suppl. 3A) 143S